2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176211
    SARS-CoV-2 Mpro-IN-45 2992608-40-7 98%
    SARS-CoV-2 Mpro-IN-45 (compound 28f) is an orally active Mpro inhibitor with IC50 values of 0.12 and 0.16 μM for HCoV-OC43 Mpro and SARS-CoV-2 Mpro, respectively. SARS-CoV-2 Mpro-IN-45 exhibits antiviral activity.
    SARS-CoV-2 Mpro-IN-45
  • HY-176223
    Antimalarial agent 51
    Antimalarial agent 51 (Compound 2) is an orally active antimalarial compound. Antimalarial agent 51 blocks nutrient uptake by Plasmodium by inhibiting the plasmodium surface anion channel (PSAC). Antimalarial agent 51 significantly inhibits the growth of Plasmodium under nutrient-restricted conditions. Combination of antimalarial agent 51 with the residual transport inhibitor PRT-2 can enhance the antimalarial effect. Antimalarial agent 51 can be used in the study of malaria targeting the PSAC channel.
    Antimalarial agent 51
  • HY-176234
    PDE4-IN-28 98%
    PDE4-IN-28 (Compound G1) is a PDE4D inhibitor (IC50: 29 nM). PDE4-IN-28 inhibits the production of TNF-α and NO (IC50: 13.32 and 2.32 μM, respectively). PDE4-IN-28 exhibits anti-inflammatory, antibacterial and analgesic effects in a rat pressure ulcer (PU) model and promotes HUVEC cell migration, thereby accelerating wound healing.
    PDE4-IN-28
  • HY-176264
    DNDI-6510
    DNDI-6510 (Compound (S)-x38) is a non-covalent SARS-CoV-2 MPro inhibitor with a IC50 of 0.04 μM. DNDI-6510 has a potent antiviral activity across SARS-CoV-2 and its variants as well as a weak efficacy to SARS-CoV-1. DNDI-6510 significantly improves drug exposure in metabolically humanized mice model (8HUM).
    DNDI-6510
  • HY-17626A
    Alalevonadifloxacin mesylate 948895-94-1 98%
    Alalevonadifloxacin (WCK-2349) mesylate is an orally active antibiotic targeting Gram-positive and Gram-negative bacteria. Alalevonadifloxacin mesylate is promising for research of acute bacterial skin and skin structure infections and hospital-acquired pneumonia caused by MRSA and other pathogens.
    Alalevonadifloxacin mesylate
  • HY-17626B
    Alalevonadifloxacin hydrochloride 396132-82-4 98%
    Alalevonadifloxacin (hydrochloride) (WCK-2349 (hydrochloride)) is a oraaly active anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic.
    Alalevonadifloxacin hydrochloride
  • HY-176413
    SDH-IN-27 98%
    SDH-IN-27 (Compound Q18) is a succinate dehydrogenase inhibitor (SDHI) (IC50: 9.7 mg/L). SDH-IN-27 induces mycelial morphology changes and lipid peroxidation, and exhibits antifungal activity against C. camelliae (EC50: 6.0 mg/L). SDH-IN-27 is an ergosterol biosynthesis inhibitor (EBI) that binds to the active site of CYP51, ultimately leading to cell death of pathogenic fungi.
    SDH-IN-27
  • HY-176433
    NSC-323241 79514-43-5
    NSC-323241 is a potent STT3A-mediated mega protein complex assembly inhibitor. NSC-323241 disrupts he endoplasmic reticulum (ER) mega complex nucleated by STT3A during dengue virus (DENV) and Zika virus (ZIKV) infection. NSC-323241 targets the binding of STT3A subcomplex with viral nonstructural proteins (e.g., NS2B, NS3) and host translocon proteins, disrupting the formation of viral replication microenvironment. NSC-323241 is promising for research of flavivirus infection, such as dengue fever and Zika virus.
    NSC-323241
  • HY-176519
    ANT2681 2270184-16-0
    ANT2681 is a potent NDM inhibitor with a Ki value of 0.04 μM against NDM-1. ANT2681 also inhibits other MBLs, such as VIM-1 and IMP-1 with Ki values of 0.63 μM and 3.81 μM, respectively. ANT2681 can be used in combination with Meropenem (HY-13678) to inhibit infections caused by NDM-producing Enterobacteriaceae.
    ANT2681
  • HY-176565
    ZN148 2190527-04-7
    ZN148 is a zinc-chelating synthetic metallo-β-lactamase (MBL) inhibitor which attenuates MBL-mediated carbapenem resistance. ZN148 can restore the in vitro clinical susceptibility to carbapenems in >98% of a large international collection of MBL-producing clinical Enterobacterales strains. ZN148 can be utilized in research on anti MBL-producing bacteria.
    ZN148
  • HY-176730
    HC2210 1185709-64-1
    HC2210 has an antibacterial effect against Mycobacterium abscessus (Mab) (EC50: 0.72 µM). HC2210 modulates the expression of Mab genes related to oxidative stress and lipid metabolism. HC2210 can be used in the study of Mab infection.
    HC2210
  • HY-176746
    CMLD009688 98%
    CMLD009688 is a cationic amphiphilic antifungal agent. CMLD009688 selectively inhibits plant pathogenic fungi such as Fusarium graminearum. CMLD009688 interacts with biological membranes, perturbing vacuolar and mitochondrial membrane structures to induce fungal cell death. CMLD009688 is promising for research of plant fungal diseases (e.g., wheat head blight, gray mold).
    CMLD009688
  • HY-176762
    TOP3B-IN-1 67047-17-0
    TOP3B-IN-1 (NSC-260610) is a Topoisomerase IIIβ (TOP3B) inhibitor. TOP3B-IN-1 fails to induce the formation of TOP3B cleavage complexes (TOP3Bccs) with both DNA and RNA, and destabilizes TOP3Bccs. TOP3B-IN-1 can be used as a control compound for the development of inhibitors targeting TOP3B.
    TOP3B-IN-1
  • HY-176793
    JAK1-IN-18 2459377-98-9 98%
    JAK1-IN-18 (Example 2) is a selective JAK1 inhibitor with an IC50 of 0.15  nM for JAK1 over JAK2 and JAK3. JAK1-IN-18 significantly reduces inflammation in DSS (HY-116282C)-induced ulcerative colitis (UC) mouse models and DNBS(HY-W324435)-induced Crohn's disease (CD) rat models. JAK1-IN-18 can be used for autoimmune diseases (such as inflammatory bowel disease), viral infections (such as HBV infection) and cancers (such as blood cancer) research.
    JAK1-IN-18
  • HY-176929
    BET-IN-29 1776060-36-6
    BET-IN-29 (Compound 1) is a bromodomain and the terminal motif (BET) inhibitor. BET-IN-29 can be used for the study of cancer, inflammation, metabolism, neurological diseases, and infectious diseases.
    BET-IN-29
  • HY-176964
    N-Choloylphenylalanine 19651-46-8 98%
    N-Choloylphenylalanine (Compound 6273) (PheCA) is a VPR-induced growth arrest inhibitor. N-Choloylphenylalanine alleviates VPR-induced growth arrest. N-Choloylphenylalanine can be used in yeast and HIV-1 infection research.
    N-Choloylphenylalanine
  • HY-176997
    PDHc-E2-IN-1 3031881-21-4
    PDHc-E2-IN-1 (Compound 9) is a Pyruvate Dehydrogenase Complex E2 (PDHc-E2) inhbibitor. with an IC50 of 2.52 μM. PDHc-E2-IN-1 shows strong antibacterial activity and can be used in the research of bacterial spot disease and bacterial leaf blight in rice.
    PDHc-E2-IN-1
  • HY-177042
    Hsp90-IN-41 909871-27-8 98%
    Hsp90-IN-41 (Compound C1) is an inhibitor of Hsp90 (IC50 = 0.044 μM). Hsp90-IN-41 exhibits antifungal and antitumor (IC50 = 0.049 μM) activities in vitro.
    Hsp90-IN-41
  • HY-177098
    Lepetegravir 2808219-64-7 98%
    Lepetegravir (Example 24) is a HIV integrase inhibitor. Lepetegravir has antiviral effects (EC50: 0.98 nM in MT-4 cells).
    Lepetegravir
  • HY-177117
    Ocipumaltib 2434602-26-1
    Ocipumaltib (Example 2) is an inhibitor of mucosa associated lymphoid tissue protein 1 (MALT1). Ocipumaltib is an antitumor agent. Ocipumaltib can be studied in research for cancer, infection, neurological and hematological diseases.
    Ocipumaltib
Cat. No. Product Name / Synonyms Application Reactivity